AR043825A1 - Procesos de preparacion de 5-(haloacetil)-8-(oxisustituidos)-(1h)-quinolin-2-onas - Google Patents

Procesos de preparacion de 5-(haloacetil)-8-(oxisustituidos)-(1h)-quinolin-2-onas

Info

Publication number
AR043825A1
AR043825A1 ARP040101105A ARP040101105A AR043825A1 AR 043825 A1 AR043825 A1 AR 043825A1 AR P040101105 A ARP040101105 A AR P040101105A AR P040101105 A ARP040101105 A AR P040101105A AR 043825 A1 AR043825 A1 AR 043825A1
Authority
AR
Argentina
Prior art keywords
quinolin
hydroxy
acetyl
substituted
oxy
Prior art date
Application number
ARP040101105A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33131902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043825(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR043825A1 publication Critical patent/AR043825A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

La presente se refiere a un procedimiento para preparar oxi-(1H)-quinolin-2-onas 5(-alfa-haloacetil)-8-sustituidas. El procedimiento involucra, (i) hacer reaccionar, (a) 8-hidroxi-(1H)-quinolin-2-ona con un agente de acilación y un ácido Lewis para formar 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; o (b) 8-hidroxi-(1H)-quinolin-2-ona con un agente de acilación para formar 8-acetoxi-(1H)-quinolin-2-ona, y tratar, in situ la 8-acetoxi-(1H)-quinolin-2-ona con un ácido Lewis para formar la 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; o (c) 8-acetoxi-(1H)-quinolin-2-ona con ácido Lewis para formar 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; (ii) hacer reaccionar la 5-acetil-8-hidroxi-(1H)-quinolin-2-ona preparada en el paso (i) con un compuesto que tiene la fórmula RL en presencia de una base y un solvente para formar oxi-(1H)-quinolin-2-ona 5-acetil-8-sustituida, en donde R es un grupo protector y L es un grupo saliente; y (iii) hacer reaccionar la oxi-(1H)-quinolin-2-ona 5-acetil-8-sustituida con un agente de halogenación en presencia de un solvente para formar oxi-(1H)-quinolin-2-ona 5-(alfa-haloacetil)-8-sustituida. Estos compuestos se utilizan como intermediarios para preparar sales de 5[( R )-2-(5,6-diehl-indan-2-ilamina)-1-hidroxi-etil]-8-hidroxi-(1H)-quinolin-2-ona. Este último compuesto es útil como agonista adrenoceptor beta-selectivos y tiene potente actividad broncodilatadora.
ARP040101105A 2003-04-02 2004-04-01 Procesos de preparacion de 5-(haloacetil)-8-(oxisustituidos)-(1h)-quinolin-2-onas AR043825A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45972403P 2003-04-02 2003-04-02

Publications (1)

Publication Number Publication Date
AR043825A1 true AR043825A1 (es) 2005-08-17

Family

ID=33131902

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP040101105A AR043825A1 (es) 2003-04-02 2004-04-01 Procesos de preparacion de 5-(haloacetil)-8-(oxisustituidos)-(1h)-quinolin-2-onas
ARP160100188A AR103508A2 (es) 2003-04-02 2016-01-25 PROCESO PARA LA PREPARACIÓN DE OXI-(1H)-QUINOLIN-2-ONAS 5-(a-HALOACETILO)-8-SUSTITUIDAS

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP160100188A AR103508A2 (es) 2003-04-02 2016-01-25 PROCESO PARA LA PREPARACIÓN DE OXI-(1H)-QUINOLIN-2-ONAS 5-(a-HALOACETILO)-8-SUSTITUIDAS

Country Status (35)

Country Link
US (1) US7605267B2 (es)
EP (1) EP1613599B8 (es)
JP (1) JP4726778B2 (es)
KR (1) KR101073740B1 (es)
CN (1) CN1774423A (es)
AR (2) AR043825A1 (es)
AT (1) ATE491690T1 (es)
AU (1) AU2004226212B2 (es)
BR (1) BRPI0409154B1 (es)
CA (1) CA2520990C (es)
CL (1) CL2004000706A1 (es)
CO (1) CO5700779A2 (es)
CY (1) CY1111515T1 (es)
DE (1) DE602004030553D1 (es)
DK (1) DK1613599T3 (es)
EC (1) ECSP056059A (es)
ES (1) ES2358193T3 (es)
HK (1) HK1086833A1 (es)
HR (1) HRP20110184T1 (es)
IL (1) IL171053A (es)
IS (1) IS2800B (es)
MA (1) MA27761A1 (es)
MX (1) MXPA05010616A (es)
MY (1) MY141871A (es)
NO (1) NO331980B1 (es)
NZ (1) NZ542623A (es)
PE (2) PE20100399A1 (es)
PL (1) PL1613599T3 (es)
PT (1) PT1613599E (es)
RU (1) RU2339621C2 (es)
SI (1) SI1613599T1 (es)
TN (1) TNSN05245A1 (es)
TW (1) TWI324151B (es)
WO (1) WO2004087668A1 (es)
ZA (1) ZA200507603B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
CN101479245B (zh) 2006-06-30 2013-05-22 诺瓦提斯公司 喹啉酮衍生物和其药物组合物
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
CN102633717B (zh) * 2012-03-30 2013-11-20 西南大学 N-乙酰-喹啉-2(1h)酮类化合物及其制备方法和应用
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP3092217B1 (en) 2014-01-09 2020-06-03 Davuluri, Ramamohan Rao A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN114751857A (zh) * 2022-04-29 2022-07-15 梯尔希(南京)药物研发有限公司 一种茚达特罗杂质的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS539228B2 (es) * 1974-01-31 1978-04-04
CA1164459A (en) * 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
JPS5896022A (ja) * 1981-11-30 1983-06-07 Otsuka Pharmaceut Co Ltd 強心剤
ES8403457A1 (es) * 1983-01-28 1984-03-16 Espanola Farma Therapeut Procedimiento para la obtencion de un compuesto derivado de la 2-quinolinona.
ES8605239A1 (es) * 1985-12-04 1986-03-16 Astur Pharma Un procedimiento para la preparacion de quinolonas sustitui-das
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt

Also Published As

Publication number Publication date
CL2004000706A1 (es) 2005-01-14
PE20050211A1 (es) 2005-04-27
TNSN05245A1 (en) 2007-06-11
ES2358193T3 (es) 2011-05-06
AU2004226212A1 (en) 2004-10-14
AR103508A2 (es) 2017-05-17
ECSP056059A (es) 2006-01-27
KR101073740B1 (ko) 2011-10-13
MY141871A (en) 2010-07-16
NZ542623A (en) 2008-07-31
MXPA05010616A (es) 2005-11-23
US20060189653A1 (en) 2006-08-24
CA2520990A1 (en) 2004-10-14
PE20100399A1 (es) 2010-06-01
NO20055099D0 (no) 2005-11-01
PL1613599T3 (pl) 2011-05-31
CA2520990C (en) 2011-08-09
NO331980B1 (no) 2012-05-21
ATE491690T1 (de) 2011-01-15
RU2339621C2 (ru) 2008-11-27
KR20050119678A (ko) 2005-12-21
JP2006522055A (ja) 2006-09-28
JP4726778B2 (ja) 2011-07-20
EP1613599B8 (en) 2011-06-22
DK1613599T3 (da) 2011-03-28
IS8095A (is) 2005-10-27
SI1613599T1 (sl) 2011-04-29
EP1613599A1 (en) 2006-01-11
US7605267B2 (en) 2009-10-20
HK1086833A1 (en) 2006-09-29
TW200504025A (en) 2005-02-01
IS2800B (is) 2012-09-15
CO5700779A2 (es) 2006-11-30
BRPI0409154A (pt) 2006-03-28
TWI324151B (en) 2010-05-01
CN1774423A (zh) 2006-05-17
MA27761A1 (fr) 2006-02-01
EP1613599B1 (en) 2010-12-15
CY1111515T1 (el) 2015-08-05
BRPI0409154B1 (pt) 2014-03-25
AU2004226212B2 (en) 2008-02-21
NO20055099L (no) 2006-01-02
DE602004030553D1 (de) 2011-01-27
IL171053A (en) 2010-12-30
PT1613599E (pt) 2011-03-17
ZA200507603B (en) 2006-11-29
WO2004087668A1 (en) 2004-10-14
HRP20110184T1 (hr) 2011-04-30

Similar Documents

Publication Publication Date Title
AR043825A1 (es) Procesos de preparacion de 5-(haloacetil)-8-(oxisustituidos)-(1h)-quinolin-2-onas
ECSP055977A (es) Procedimiento para preparar la sal de 5-[(r)-2(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona, útil como un agonista de adrenoceptor
BRPI0415855A (pt) processo para preparação de ésteres de ácido 2-dihalogenacil-3-amino-acrìlico e ésteres de ácido 3-dihalogeno-metil-pirazol-4-carboxìlico
AR063710A1 (es) Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden.
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
AR109669A1 (es) Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano
CR8358A (es) Pentalones transpuestos, un metodo para prepararlos y su uso como antiinflamatorios
BR112016028273A8 (pt) derivados radiorrotulados de composto de 2-amino6-fluoro-n-[5-fluoro-piridin-3-il]-pirazol[1,5-a]pirimidin3-carboxamida úteis como inibidor de atr cinase, processo para preparação do referido composto, bem como diferentes formas sólidas do mesmo, uso destas, e composição farmacêutica
PA8676301A1 (es) Metodos para sintetizar derivados de 6-alquilaminoquinolina
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
BRPI0612475B8 (pt) métodos para a preparação de um composto
BRPI0508102A (pt) inibidores de caspase e usos dos mesmos
SV2006002190A (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiaxolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
AR071548A1 (es) Amidas de acido 3-substituido-4-oxo-3, 4-dihidro-imidazo[5, 1-d]1, 2, 3, 5-tetracina-8-carboxilico, un metodo para su preparacion e intermediarios de su sintesis, una composicion farmaceutica que las comprende y su uso en la fabricacion de medicamentos para el tratamiento de diversos tipos de cancer
BRPI0407282A (pt) Processo para preparação de inibidores de pirrolotriazina cinase
PE20091359A1 (es) Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina
AR057451A1 (es) Metodos para preparar derivados de acido glutamico
AR053722A2 (es) Procedimiento para preparar secretagogos de hormonas del crecimiento y poliformo de los compuestos obtenidos
BRPI0411308A8 (pt) Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
ATE513801T1 (de) Verfahren zur synthese von propargylatierten aminoindanderivativen
MX3413E (es) Procedimientos para la preparacion de 1-(3 o 4-fenoxifenil) piperazina
BR112022002990A2 (pt) Processo para a preparação de derivados de ácido carboxílico de 3-bromo-4,5-di-hidro-1h-pirazóis
AR038055A1 (es) Proceso para preparar 2- (fenilo sustituido) - 2 - hidroxi - etil carbamatos.
DE60334627D1 (de) Verfahren zur herstellung eines 3,5-dihydroxy-6-heptenoats
BRPI0512967A (pt) processo de preparação de derivados de hidroxiacetofenona, processo de preparação de derivados de 4-oxo-4h-cromen-3-carbaldeìdo, derivados de hidroxiacetofenona, derivados de 4-oxo-4h-cromen-3-carbaldeìdo, composições farmacêuticas compreendendo os mesmos e usos dos referidos derivados na preparação de composições farmacêuticas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee